Coregulator function: a key to understanding tissue specificity of selective receptor modulators.
暂无分享,去创建一个
[1] W. Wahli,et al. Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.
[2] B. O’Malley,et al. Specificity of thyroid hormone receptor subtype and steroid receptor coactivator-1 on thyroid hormone action. , 2003, American journal of physiology. Endocrinology and metabolism.
[3] P. Meltzer,et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.
[4] P. Chambon,et al. Thyroid function in mice with compound heterozygous and homozygous disruptions of SRC-1 and TIF-2 coactivators: evidence for haploinsufficiency. , 2002, Endocrinology.
[5] J R Wood,et al. Allosteric modulation of estrogen receptor conformation by different estrogen response elements. , 2001, Molecular endocrinology.
[6] B. O’Malley,et al. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. , 1998, Science.
[7] C. Allis,et al. Hormone-dependent, CARM1-directed, arginine-specific methylation of histone H3 on a steroid-regulated promoter , 2001, Current Biology.
[8] B. O’Malley,et al. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. , 1997, Molecular endocrinology.
[9] R. Goodman,et al. CBP/p300 in cell growth, transformation, and development. , 2000, Genes & development.
[10] K. Bramlett,et al. Effects of selective estrogen receptor modulators (SERMs) on coactivator nuclear receptor (NR) box binding to estrogen receptors. , 2002, Molecular genetics and metabolism.
[11] J. Gustafsson,et al. A regulatory role for RIP140 in nuclear receptor activation. , 1998, Molecular endocrinology.
[12] H. Masuya,et al. Abnormal skeletal patterning in embryos lacking a single Cbp allele: a partial similarity with Rubinstein-Taybi syndrome. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[13] B. O’Malley,et al. Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486 , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[14] Myles Brown,et al. Molecular Determinants for the Tissue Specificity of SERMs , 2002, Science.
[15] K. Chwalisz,et al. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium , 2000, Steroids.
[16] D. McDonnell,et al. Evaluation of ligand-dependent changes in AR structure using peptide probes. , 2002, Molecular endocrinology.
[17] P. Chambon,et al. The Function of TIF2/GRIP1 in Mouse Reproduction Is Distinct from Those of SRC-1 and p/CIP , 2002, Molecular and Cellular Biology.
[18] N. Weigel. Steroid hormone receptors and their regulation by phosphorylation. , 1996, The Biochemical journal.
[19] L. Espinosa,et al. IκBα and p65 Regulate the Cytoplasmic Shuttling of Nuclear Corepressors: Cross-talk between Notch and NFκB Pathways , 2003 .
[20] B. Katzenellenbogen,et al. An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[21] D. Livingston,et al. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. , 2000, Genes & development.
[22] Guillaume Adelmant,et al. Activation of PPARγ coactivator-1 through transcription factor docking , 1999 .
[23] Kristen Jepsen,et al. Combinatorial Roles of the Nuclear Receptor Corepressor in Transcription and Development , 2000, Cell.
[24] D. Latchman,et al. Nerve Growth Factor Up-regulates the Transcriptional Activity of CBP through Activation of the p42/p44MAPK Cascade* , 1998, The Journal of Biological Chemistry.
[25] David M. Heery,et al. A signature motif in transcriptional co-activators mediates binding to nuclear receptors , 1997, Nature.
[26] K. Grandien,et al. Printed in U.S.A. Copyright © 1997 by The Endocrine Society Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors � and � , 2022 .
[27] Kristina Schoonjans,et al. Thiazolidinediones: an update , 2000, The Lancet.
[28] D. Robyr,et al. Nuclear hormone receptor coregulators in action: diversity for shared tasks. , 2000, Molecular endocrinology.
[29] J. Cidlowski,et al. The glucocorticoid receptor: coding a diversity of proteins and responses through a single gene. , 2002, Molecular endocrinology.
[30] C. J. Barnes,et al. A naturally occurring MTA1 variant sequesters oestrogen receptor-α in the cytoplasm , 2002, Nature.
[31] T. Powles,et al. Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial , 2004, Breast Cancer Research and Treatment.
[32] P. Chambon,et al. The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function , 1988, Cell.
[33] E. Jensen,et al. Binding of antiestrogens exposes an occult antigenic determinant in the human estrogen receptor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[34] A. Beaudet,et al. Genetic Ablation of the Steroid Receptor Coactivator-Ubiquitin Ligase, E6-AP, Results in Tissue-Selective Steroid Hormone Resistance and Defects in Reproduction , 2002, Molecular and Cellular Biology.
[35] B. O’Malley,et al. Phosphorylation of Steroid Receptor Coactivator-1 , 2000, The Journal of Biological Chemistry.
[36] O. Hermanson,et al. Regulation of somatic growth by the p160 coactivator p/CIP. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[37] M. Harper,et al. Contrasting Endocrine Activities of cis and trans Isomers in a Series of Substituted Triphenylethylenes , 1966, Nature.
[38] R. Roeder,et al. The TRAP/SMCC/Mediator complex and thyroid hormone receptor function , 2001, Trends in Endocrinology & Metabolism.
[39] Y. Matsuo,et al. Identification of a Series of Transforming Growth Factor β-Responsive Genes by Retrovirus-Mediated Gene Trap Screening , 2000, Molecular and Cellular Biology.
[40] S. Tsai,et al. Cdc25B Functions as a Novel Coactivator for the Steroid Receptors , 2001, Molecular and Cellular Biology.
[41] Carolyn L. Smith,et al. Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains. , 2003, Molecular endocrinology.
[42] J. Kurebayashi,et al. Expression Levels of Estrogen Receptor-α, Estrogen Receptor-β, Coactivators, and Corepressors in Breast Cancer , 2000 .
[43] R. Evans,et al. Nuclear Receptor Coactivator ACTR Is a Novel Histone Acetyltransferase and Forms a Multimeric Activation Complex with P/CAF and CBP/p300 , 1997, Cell.
[44] Yuanzheng He,et al. Modulation of Induction Properties of Glucocorticoid Receptor-Agonist and -Antagonist Complexes by Coactivators Involves Binding to Receptors but Is Independent of Ability of Coactivators to Augment Transactivation* , 2002, The Journal of Biological Chemistry.
[45] G. Chetrite,et al. Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. , 1997, Anticancer research.
[46] Kenneth P Nephew,et al. The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells. , 2003, Molecular endocrinology.
[47] B. O’Malley,et al. Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily , 1995, Science.
[48] M. Imhof,et al. Yeast RSP5 and its human homolog hRPF1 potentiate hormone-dependent activation of transcription by human progesterone and glucocorticoid receptors , 1996, Molecular and cellular biology.
[49] T. Kouzarides,et al. Methylation at arginine 17 of histone H3 is linked to gene activation , 2002, EMBO reports.
[50] Carolyn L. Smith,et al. Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actions , 2002, Steroids.
[51] C. Glass,et al. SAP30, a component of the mSin3 corepressor complex involved in N-CoR-mediated repression by specific transcription factors. , 1998, Molecular cell.
[52] Simak Ali,et al. Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. , 2000, Molecular cell.
[53] Regulation of glucocorticoid receptor activity by 14--3-3-dependent intracellular relocalization of the corepressor RIP140. , 2001, Molecular endocrinology.
[54] C. Klinge. Estrogen receptor interaction with estrogen response elements. , 2001, Nucleic acids research.
[55] D. Edwards,et al. Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. , 1992, The Journal of biological chemistry.
[56] M. Tsai,et al. The Angelman Syndrome-Associated Protein, E6-AP, Is a Coactivator for the Nuclear Hormone Receptor Superfamily , 1999, Molecular and Cellular Biology.
[57] R. Weiss,et al. Mice deficient in the steroid receptor co‐activator 1 (SRC‐1) are resistant to thyroid hormone , 1999, The EMBO journal.
[58] I. Weinstein,et al. Inhibition of histone acetyltransferase function of p300 by PKCdelta. , 2002, Biochimica et biophysica acta.
[59] K. Umesono,et al. SMRT isoforms mediate repression and anti-repression of nuclear receptor heterodimers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[60] K. Chwalisz,et al. Selective Progesterone Receptor Modulators (SPRMs) , 2002, Annals of the New York Academy of Sciences.
[61] P. Chambon,et al. Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[62] Marc Montminy,et al. A Transcriptional Switch Mediated by Cofactor Methylation , 2001, Science.
[63] J. Sumpter,et al. Differential Effects of Xenoestrogens on Coactivator Recruitment by Estrogen Receptor (ER) α and ERβ* , 2000, The Journal of Biological Chemistry.
[64] O. Jänne,et al. PIAS Proteins Modulate Transcription Factors by Functioning as SUMO-1 Ligases , 2002, Molecular and Cellular Biology.
[65] M. D. Leibowitz,et al. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. , 1996, Endocrinology.
[66] B. O’Malley,et al. Reduction of coactivator expression by antisense oligodeoxynucleotides inhibits ERalpha transcriptional activity and MCF-7 proliferation. , 2002, Molecular endocrinology.
[67] V. Giguère,et al. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. , 1999, Molecular cell.
[68] R. Renkawitz,et al. RU486-induced Glucocorticoid Receptor Agonism Is Controlled by the Receptor N Terminus and by Corepressor Binding* , 2002, The Journal of Biological Chemistry.
[69] D. Agard,et al. Estrogen receptor pathways to AP-1 , 2000, The Journal of Steroid Biochemistry and Molecular Biology.
[70] Carolyn L. Smith,et al. Intracellular signaling pathways: nongenomic actions of estrogens and ligand-independent activation of estrogen receptors. , 2001, Frontiers in bioscience : a journal and virtual library.
[71] Jiandie D. Lin,et al. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. , 2001, Molecular cell.
[72] S. Ishii,et al. Extensive brain hemorrhage and embryonic lethality in a mouse null mutant of CREB-binding protein , 2000, Mechanisms of Development.
[73] Neil J. McKenna,et al. Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators , 2002, Cell.
[74] V. Giguère,et al. Contribution of steroid receptor coactivator-1 and CREB binding protein in ligand-independent activity of estrogen receptor β , 2001, The Journal of Steroid Biochemistry and Molecular Biology.
[75] J. Gorski,et al. A ligand-induced conformational change in the estrogen receptor is localized in the steroid binding domain. , 1992, Biochemistry.
[76] Myles Brown,et al. Polarity-specific activities of retinoic acid receptors determined by a co-repressor , 1995, Nature.
[77] Hui Li,et al. The Receptor-associated Coactivator 3 Activates Transcription through CREB-binding Protein Recruitment and Autoregulation* , 1998, The Journal of Biological Chemistry.
[78] B. Katzenellenbogen,et al. Direct Acetylation of the Estrogen Receptor α Hinge Region by p300 Regulates Transactivation and Hormone Sensitivity* , 2001, The Journal of Biological Chemistry.
[79] J. Torchia,et al. Microtubule-Dependent Subcellular Redistribution of the Transcriptional Coactivator p/CIP , 2002, Molecular and Cellular Biology.
[80] E. Mulder,et al. Ligand-induced Conformational Alterations of the Androgen Receptor Analyzed by Limited Trypsinization , 1995, The Journal of Biological Chemistry.
[81] S. Inoue,et al. Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors alpha and beta. , 1997, Biochemical and biophysical research communications.
[82] B. O’Malley,et al. Progesterone and Glucocorticoid Receptors Recruit Distinct Coactivator Complexes and Promote Distinct Patterns of Local Chromatin Modification , 2003 .
[83] P. Chambon,et al. Differential ligand‐dependent interactions between the AF‐2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. , 1996, The EMBO journal.
[84] J. Morley,et al. Biological actions of androgens. , 1987, Endocrine reviews.
[85] C. Deng,et al. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[86] R. Lanz,et al. Nuclear receptor coregulators: cellular and molecular biology. , 1999, Endocrine reviews.
[87] L. Sorbera,et al. ROSIGLITAZONE MALEATE : PROP INNM , 1998 .
[88] C. Glass,et al. The coregulator exchange in transcriptional functions of nuclear receptors. , 2000, Genes & development.
[89] M. Parker,et al. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[90] Christopher K. Glass,et al. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function , 1997, Nature.
[91] B. O’Malley,et al. The 26S Proteasome Is Required for Estrogen Receptor-α and Coactivator Turnover and for Efficient Estrogen Receptor-α Transactivation , 2000 .
[92] Min Xu,et al. Steroid-induced Conformational Changes at Ends of the Hormone-binding Domain in the Rat Glucocorticoid Receptor Are Independent of Agonist Versus Antagonist Activity* , 1997, The Journal of Biological Chemistry.
[93] Bert W O'Malley,et al. Coordinate Regulation of Transcription and Splicing by Steroid Receptor Coregulators , 2002, Science.
[94] J. Qin,et al. Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator Activity by IκB Kinase , 2002, Molecular and Cellular Biology.
[95] E. Wilson,et al. Steroid receptor coactivator expression throughout the menstrual cycle in normal and abnormal endometrium. , 2002, The Journal of clinical endocrinology and metabolism.
[96] G. Giannoukos,et al. New antiprogestins with partial agonist activity: potential selective progesterone receptor modulators (SPRMs) and probes for receptor- and coregulator-induced changes in progesterone receptor induction properties. , 2001, Molecular endocrinology.
[97] B. O’Malley,et al. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. , 1994, Annual review of biochemistry.
[98] B. O’Malley,et al. FRAP reveals that mobility of oestrogen receptor-alpha is ligand- and proteasome-dependent. , 2001, Nature cell biology.
[99] J. Gustafsson,et al. Functional Differences between the Amino-Terminal Domains of Estrogen Receptors α and β , 2000 .
[100] B. O’Malley,et al. Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. , 1993, Molecular endocrinology.
[101] Zbigniew Dauter,et al. Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.
[102] L Zhi,et al. Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone. , 1999, Bioorganic & medicinal chemistry letters.
[103] G. Mellgren,et al. The nuclear receptor coactivators p300/CBP/cointegrator-associated protein (p/CIP) and transcription intermediary factor 2 (TIF2) differentially regulate PKA-stimulated transcriptional activity of steroidogenic factor 1. , 2002, Molecular endocrinology.
[104] Hui Li,et al. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[105] John H. White,et al. Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms. , 2003, Molecular cell.
[106] R. Turner,et al. Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[107] J. Corton,et al. Interaction of Estrogenic Chemicals and Phytoestrogens with Estrogen Receptor β. , 1998, Endocrinology.
[108] J. Katzenellenbogen,et al. Estrogen receptor dimerization: ligand binding regulates dimer affinity and dimer dissociation rate. , 2002, Molecular endocrinology.
[109] David A. Agard,et al. The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.
[110] M. Sporn,et al. Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). , 2001, Trends in molecular medicine.
[111] H Grøn,et al. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[112] C. Christiansen,et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.
[113] A. Wellstein,et al. A role for TGF-β in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells , 2002, Oncogene.
[114] N. Webster,et al. The human estrogen receptor has two independent nonacidic transcriptional activation functions , 1989, Cell.
[115] W. Baumeister,et al. The 26S proteasome: a molecular machine designed for controlled proteolysis. , 1999, Annual review of biochemistry.
[116] D. Fowlkes,et al. Dissection of the LXXLL Nuclear Receptor-Coactivator Interaction Motif Using Combinatorial Peptide Libraries: Discovery of Peptide Antagonists of Estrogen Receptors α and β , 1999, Molecular and Cellular Biology.
[117] R. Turner,et al. Dose-dependent effects of tamoxifen on long bones in growing rats: influence of ovarian status. , 1991, Endocrinology.
[118] J. Auwerx,et al. SRC-1 and TIF2 Control Energy Balance between White and Brown Adipose Tissues , 2002, Cell.
[119] B. Komm,et al. Structure-function evaluation of ER alpha and beta interplay with SRC family coactivators. ER selective ligands. , 2001, Biochemistry.
[120] J. Davie,et al. Direct visualization of the human estrogen receptor alpha reveals a role for ligand in the nuclear distribution of the receptor. , 1999, Molecular biology of the cell.
[121] W. Chin,et al. Identification and Characterization of a Tissue-Specific Coactivator, GT198, That Interacts with the DNA-Binding Domains of Nuclear Receptors , 2022 .
[122] Thorsten Heinzel,et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor , 1995, Nature.
[123] K. Nephew,et al. Expression of Estrogen Receptor Coactivators in the Rat Uterus1 , 2000, Biology of reproduction.
[124] V. Cavaillès,et al. Estrogen receptor cofactors expression in breast and endometrial human cancer cells , 1999, Molecular and Cellular Endocrinology.
[125] C. Glass,et al. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. , 1998, Genes & development.
[126] P. Driggers,et al. Estrogen action and cytoplasmic signaling cascades. Part I: membrane-associated signaling complexes , 2002, Trends in Endocrinology & Metabolism.
[127] Wolfgang Baumeister,et al. The Proteasome: Paradigm of a Self-Compartmentalizing Protease , 1998, Cell.
[128] K. Bramlett,et al. Ser-884 adjacent to the LXXLL motif of coactivator TRBP defines selectivity for ERs and TRs. , 2002, Molecular endocrinology.
[129] E. Kalkhoven,et al. AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors , 1997, Molecular and cellular biology.
[130] J. Gustafsson,et al. Differential Recruitment of the Mammalian Mediator Subunit TRAP220 by Estrogen Receptors ERα and ERβ* , 2001, The Journal of Biological Chemistry.
[131] A. Baniahmad,et al. The amino terminus of the human AR is target for corepressor action and antihormone agonism. , 2002, Molecular endocrinology.
[132] J. Gustafsson,et al. Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[133] C. Glass,et al. A complex containing N-CoR, mSln3 and histone deacetylase mediates transcriptional repression , 1997, nature.
[134] Mike Clarke,et al. Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[135] J. Palvimo,et al. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[136] P. Chambon,et al. Steroid hormone receptors compete for factors that mediate their enhancer function , 1989, Cell.
[137] G. Chetrite,et al. The selective estrogen enzyme modulator (SEEM) in breast cancer , 2001, The Journal of Steroid Biochemistry and Molecular Biology.
[138] H. Seo,et al. Steroid receptor coactivator-1 deficiency causes variable alterations in the modulation of T(3)-regulated transcription of genes in vivo. , 2002, Endocrinology.
[139] F. S. French,et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. , 2001, Cancer research.
[140] S. Cowley,et al. Estrogen Receptors α and β Form Heterodimers on DNA* , 1997, The Journal of Biological Chemistry.
[141] D. McDonnell,et al. The Human Estrogen Receptor-α Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor Modulators* , 2001, The Journal of Biological Chemistry.
[142] P Chambon,et al. Two distinct estrogen‐regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. , 1990, The EMBO journal.
[143] A. Nordheim,et al. MAP kinase-dependent transcriptional coactivation by Elk-1 and its cofactor CBP. , 1996, Biochemical and biophysical research communications.
[144] S. Cl,et al. Intracellular signaling pathways: nongenomic actions of estrogens and ligand-independent activation of estrogen receptors. , 2001 .
[145] W. Chin,et al. Thyroid hormone receptor-binding protein, an LXXLL motif-containing protein, functions as a general coactivator. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[146] Bruce A. Johnson,et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. , 2003, Molecular endocrinology.
[147] S. Nemoto,et al. Identification of a specific molecular repressor of the peroxisome proliferator-activated receptor gamma Coactivator-1 alpha (PGC-1alpha). , 2002, The Journal of biological chemistry.
[148] D. McDonnell,et al. Development of peptide antagonists that target estrogen receptor–cofactor interactions , 2000, The Journal of Steroid Biochemistry and Molecular Biology.
[149] C. Lange,et al. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[150] B. O’Malley,et al. The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor , 1992, Cell.
[151] J. Gustafsson,et al. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. , 1998, Molecular pharmacology.
[152] D. McDonnell,et al. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. , 1999, Endocrinology.
[153] B. Katzenellenbogen,et al. Transcription Activation by the Human Estrogen Receptor Subtypeβ (ERβ) Studied with ERβ and ERα Receptor Chimeras* *This work was supported by NIH Grants CA-18119 and CA-60514 (to B.S.K.). , 1998, Endocrinology.
[154] S. Jentsch,et al. Ubiquitin and proteasomes: Sumo, ubiquitin's mysterious cousin , 2001, Nature Reviews Molecular Cell Biology.
[155] J. Edwards,et al. New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone. , 1998, Bioorganic & medicinal chemistry letters.
[156] S. Simons,et al. Opposing effects of corepressor and coactivators in determining the dose-response curve of agonists, and residual agonist activity of antagonists, for glucocorticoid receptor-regulated gene expression. , 1999, Molecular endocrinology.
[157] D. Fowlkes,et al. Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta. , 1999, Molecular and cellular biology.
[158] R. Darnell,et al. Involvement of the TRAP220 component of the TRAP/SMCC coactivator complex in embryonic development and thyroid hormone action. , 2000, Molecular cell.
[159] P. Chambon,et al. TIF2, a 160 kDa transcriptional mediator for the ligand‐dependent activation function AF‐2 of nuclear receptors. , 1996, The EMBO journal.
[160] L. Murphy,et al. Altered expression of estrogen receptor coregulators during human breast tumorigenesis. , 2000, Cancer research.
[161] Thorsten Heinzel,et al. A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors , 1996, Cell.
[162] M. Guenther,et al. Proteasomal regulation of nuclear receptor corepressor-mediated repression. , 1998, Genes & development.
[163] D. DeFranco,et al. Glucocorticoid receptors in hippocampal neurons that do not engage proteasomes escape from hormone-dependent down-regulation but maintain transactivation activity. , 2002, Molecular endocrinology.
[164] J. Gustafsson,et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. , 1997, Science.
[165] D. Thompson,et al. Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. , 2000, Endocrinology.
[166] B. O’Malley,et al. Reproductive functions of progesterone receptors. , 2002, Recent progress in hormone research.
[167] R. Russell,et al. A dynamic structural model for estrogen receptor-alpha activation by ligands, emphasizing the role of interactions between distant A and E domains. , 2002, Molecular cell.
[168] Zhi-Ren Liu. p68 RNA Helicase Is an Essential Human Splicing Factor That Acts at the U1 snRNA-5′ Splice Site Duplex , 2002, Molecular and Cellular Biology.
[169] O. Hermanson,et al. Nuclear receptor coregulators: multiple modes of modification , 2002, Trends in Endocrinology & Metabolism.
[170] R. Evans,et al. Activation and repression by nuclear hormone receptors: hormone modulates an equilibrium between active and repressive states , 1996, Molecular and cellular biology.
[171] M. Southey,et al. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. , 2001, Cancer research.
[172] R. Evans,et al. Regulation of Hormone-Induced Histone Hyperacetylation and Gene Activation via Acetylation of an Acetylase , 1999, Cell.
[173] Donald P. McDonnell,et al. The Opposing Transcriptional Activities of the Two Isoforms of the Human Progesterone Receptor Are Due to Differential Cofactor Binding , 2000, Molecular and Cellular Biology.
[174] Y. Niu,et al. Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer , 2002, British Journal of Cancer.
[175] J. C. Ghosh,et al. Regulation of Androgen Receptor Activity by the Nuclear Receptor Corepressor SMRT* , 2003, The Journal of Biological Chemistry.
[176] P. Jones,et al. Activation of Transcription by Estrogen Receptor α and β Is Cell Type- and Promoter-dependent* , 1999, The Journal of Biological Chemistry.
[177] D. Metzger,et al. Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor alpha. , 1999, Molecular and cellular biology.
[178] Carolyn L. Smith,et al. Mechanistic Differences in the Activation of Estrogen Receptor-α (ERα)- and ERβ-dependent Gene Expression by cAMP Signaling Pathway(s)* , 2003, The Journal of Biological Chemistry.
[179] M. Nakane,et al. A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. , 2003, Molecular endocrinology.
[180] O. Jänne,et al. The Nuclear Receptor Interaction Domain of GRIP1 Is Modulated by Covalent Attachment of SUMO-1* , 2002, The Journal of Biological Chemistry.
[181] A. Balen,et al. Polycystic ovary syndrome and cancer. , 2001, Human reproduction update.
[182] N. Weigel,et al. 8-Bromo-Cyclic AMP Induces Phosphorylation of Two Sites in SRC-1 That Facilitate Ligand-Independent Activation of the Chicken Progesterone Receptor and Are Critical for Functional Cooperation between SRC-1 and CREB Binding Protein , 2000, Molecular and Cellular Biology.
[183] S. Schreiber,et al. Nuclear Receptor Repression Mediated by a Complex Containing SMRT, mSin3A, and Histone Deacetylase , 1997, Cell.
[184] J. Shabanowitz,et al. Androgen Receptor Phosphorylation , 2002, The Journal of Biological Chemistry.
[185] M. Parker,et al. Steroid and related receptors. , 1993, Current opinion in cell biology.
[186] C. Glass,et al. Molecular determinants of nuclear receptor-corepressor interaction. , 1999, Genes & development.
[187] M. Privalsky,et al. The SMRT Corepressor Is Regulated by a MEK-1 Kinase Pathway: Inhibition of Corepressor Function Is Associated with SMRT Phosphorylation and Nuclear Export , 2000, Molecular and Cellular Biology.
[188] Jeffrey A. Lefstin,et al. Allosteric effects of DNA on transcriptional regulators , 1998, Nature.
[189] B. O’Malley,et al. Sequential recruitment of steroid receptor coactivator-1 (SRC-1) and p300 enhances progesterone receptor-dependent initiation and reinitiation of transcription from chromatin , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[190] M. Pazin,et al. What's Up and Down with Histone Deacetylation and Transcription? , 1997, Cell.
[191] J. Lees,et al. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. , 1992, The EMBO journal.
[192] Jason D. Hoeksema,et al. Analysis of Estrogen Receptor Interaction with a Repressor of Estrogen Receptor Activity (REA) and the Regulation of Estrogen Receptor Transcriptional Activity by REA* , 2000, The Journal of Biological Chemistry.
[193] J B Lawrence,et al. Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. , 1994, Genes & development.
[194] F. Saatcioglu,et al. DNA Binding-independent Transcriptional Activation by the Androgen Receptor through Triggering of Coactivators* , 2001, The Journal of Biological Chemistry.
[195] Hui Li,et al. The Human Homologue of the Yeast DNA Repair and TFIIH Regulator MMS19 Is an AF-1-specific Coactivator of Estrogen Receptor* , 2001, The Journal of Biological Chemistry.
[196] J. Font de Mora,et al. AIB1 Is a Conduit for Kinase-Mediated Growth Factor Signaling to the Estrogen Receptor , 2000, Molecular and Cellular Biology.
[197] J. Auwerx,et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. , 2001, Molecular cell.
[198] W. Wahli,et al. A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity. , 2002, Molecular endocrinology.
[199] David Newsome,et al. Gene Dosage–Dependent Embryonic Development and Proliferation Defects in Mice Lacking the Transcriptional Integrator p300 , 1998, Cell.
[200] R B Mazess,et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.
[201] Anne E Carpenter,et al. Regulation of Nuclear Receptor Transcriptional Activity by a Novel DEAD Box RNA Helicase (DP97)* , 2003, The Journal of Biological Chemistry.
[202] Yang Shi,et al. Stimulation of p300-mediated Transcription by the Kinase MEKK1* , 2001, The Journal of Biological Chemistry.
[203] J. Gustafsson,et al. Inactivation of the Nuclear Receptor Coactivator RAP250 in Mice Results in Placental Vascular Dysfunction , 2003, Molecular and Cellular Biology.
[204] J. Ellenberg,et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. , 2003, Molecular cell.
[205] N. Weigel,et al. The Nuclear Corepressors NCoR and SMRT Are Key Regulators of Both Ligand- and 8-Bromo-Cyclic AMP-Dependent Transcriptional Activity of the Human Progesterone Receptor , 1998, Molecular and Cellular Biology.
[206] Carolyn L. Smith,et al. Subnuclear Trafficking of Estrogen Receptor-α and Steroid Receptor Coactivator-1 , 2000 .
[207] J. Cidlowski,et al. Molecular identification and characterization of a and b forms of the glucocorticoid receptor. , 2001, Molecular endocrinology.
[208] A. Negro-Vilar. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. , 1999, The Journal of clinical endocrinology and metabolism.
[209] M. Erdos,et al. p300 Modulates the BRCA1 inhibition of estrogen receptor activity. , 2002, Cancer research.
[210] B. Katzenellenbogen,et al. Estrogen receptor activation function 1 works by binding p160 coactivator proteins. , 1998, Molecular endocrinology.
[211] P. Puigserver,et al. Direct coupling of transcription and mRNA processing through the thermogenic coactivator PGC-1. , 2000, Molecular cell.
[212] Wenbo Yang,et al. Regulation of Transcription by AMP-activated Protein Kinase , 2001, The Journal of Biological Chemistry.
[213] S. Robinson,et al. Species-specific pharmacology of antiestrogens: role of metabolism. , 1987, Federation proceedings.
[214] M. Parker,et al. Interaction of proteins with transcriptionally active estrogen receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[215] I. Bièche,et al. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[216] S. Kato,et al. Retracted: A subfamily of RNA‐binding DEAD‐box proteins acts as an estrogen receptor α coactivator through the N‐terminal activation domain (AF‐1) with an RNA coactivator, SRA , 2001 .
[217] Nicholas Bruchovsky,et al. Ligand-independent Activation of the Androgen Receptor by Interleukin-6 and the Role of Steroid Receptor Coactivator-1 in Prostate Cancer Cells* , 2002, The Journal of Biological Chemistry.
[218] R. Haché,et al. Attenuation of glucocorticoid signaling through targeted degradation of p300 via the 26S proteasome pathway. , 2002, Molecular endocrinology.
[219] B. O’Malley,et al. Ligand-dependent conformational changes in thyroid hormone and retinoic acid receptors are potentially enhanced by heterodimerization with retinoic X receptor , 1993, The Journal of Steroid Biochemistry and Molecular Biology.
[220] F. Miralles,et al. Characterization of the proximal estrogen-responsive element of human cathepsin D gene. , 1994, Molecular endocrinology.
[221] J. Lindgren,et al. Effects of anti-estrogens on bone in castrated and intact female rats , 1987, Breast Cancer Research and Treatment.
[222] D. Lannigan. Estrogen receptor phosphorylation , 2003, Steroids.
[223] L. Freedman,et al. Reciprocal Recruitment of DRIP/Mediator and p160 Coactivator Complexes in Vivo by Estrogen Receptor* , 2002, The Journal of Biological Chemistry.
[224] M. Garabedian,et al. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors , 1997, Molecular and cellular biology.
[225] B. Deroo,et al. Proteasome Inhibitors Reduce Luciferase and β-Galactosidase Activity in Tissue Culture Cells* , 2002, The Journal of Biological Chemistry.
[226] D. McDonnell,et al. A negative coregulator for the human ER. , 2002, Molecular endocrinology.
[227] B. O’Malley,et al. The tau 4 activation domain of the thyroid hormone receptor is required for release of a putative corepressor(s) necessary for transcriptional silencing , 1995, Molecular and cellular biology.
[228] A. Nardulli,et al. Estrogen Response Elements Alter Coactivator Recruitment through Allosteric Modulation of Estrogen Receptor β Conformation* , 2001, The Journal of Biological Chemistry.
[229] J. Wood,et al. Interaction of estrogen receptors α and β with estrogen response elements , 2001, Molecular and Cellular Endocrinology.
[230] S. Davis,et al. Androgen replacement in women: a commentary. , 1999, The Journal of clinical endocrinology and metabolism.
[231] K. Nephew,et al. The activating enzyme of NEDD8 inhibits steroid receptor function. , 2002, Molecular endocrinology.
[232] K. Korach,et al. Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements. , 2002, Molecular endocrinology.
[233] S. Misiti,et al. Expression and hormonal regulation of coactivator and corepressor genes. , 1998, Endocrinology.
[234] Mark Ptashne,et al. Negative effect of the transcriptional activator GAL4 , 1988, Nature.
[235] Chawnshang Chang,et al. Proteasome Activity Is Required for Androgen Receptor Transcriptional Activity via Regulation of Androgen Receptor Nuclear Translocation and Interaction with Coregulators in Prostate Cancer Cells* , 2002, The Journal of Biological Chemistry.
[236] P. Chambon,et al. TFIIH Interacts with the Retinoic Acid Receptor γ and Phosphorylates Its AF-1-activating Domain through cdk7* , 2000, The Journal of Biological Chemistry.
[237] J. Thomsen,et al. Mechanisms of estrogen action. , 2001, Physiological reviews.
[238] I. Todd,et al. A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474 , 1971, British Journal of Cancer.
[239] A. Takeshita,et al. Molecular cloning and properties of a full-length putative thyroid hormone receptor coactivator. , 1996, Endocrinology.
[240] J. Pike,et al. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. , 1995, Molecular endocrinology.
[241] S. Cowley,et al. A comparison of transcriptional activation by ERα and ERβ , 1999, The Journal of Steroid Biochemistry and Molecular Biology.
[242] E. Yeh,et al. Ubiquitin-like proteins: new wines in new bottles. , 2000, Gene.
[243] J. Thomsen,et al. DAX-1 Functions as an LXXLL-containing Corepressor for Activated Estrogen Receptors* , 2000, The Journal of Biological Chemistry.
[244] D. Trouche,et al. Control of CBP co‐activating activity by arginine methylation , 2002, The EMBO journal.
[245] D. DeFranco,et al. Proteasomal Inhibition Enhances Glucocorticoid Receptor Transactivation and Alters Its Subnuclear Trafficking , 2002, Molecular and Cellular Biology.
[246] Xiaodong Cheng,et al. Synergy among Nuclear Receptor Coactivators: Selective Requirement for Protein Methyltransferase and Acetyltransferase Activities , 2002, Molecular and Cellular Biology.
[247] Neil J McKenna,et al. A Steroid Receptor Coactivator, SRA, Functions as an RNA and Is Present in an SRC-1 Complex , 1999, Cell.
[248] M. Erdos,et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. , 1999, Science.
[249] R. Shiu,et al. Mechanism of estrogen activation of c-myc oncogene expression. , 1992, Oncogene.
[250] D. Aswad,et al. Regulation of transcription by a protein methyltransferase. , 1999, Science.
[251] E. Treuter,et al. Cloning and Characterization of RAP250, a Novel Nuclear Receptor Coactivator* , 2000, The Journal of Biological Chemistry.
[252] Simak Ali,et al. Human Estrogen Receptor β Binds DNA in a Manner Similar to and Dimerizes with Estrogen Receptor α* , 1997, The Journal of Biological Chemistry.
[253] Johan Malm,et al. Selective thyroid hormone receptor-β activation: A strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[254] Neil J McKenna,et al. Hierarchical Affinities and a Bipartite Interaction Model for Estrogen Receptor Isoforms and Full-length Steroid Receptor Coactivator (SRC/p160) Family Members* , 2003, The Journal of Biological Chemistry.
[255] P. Giangrande,et al. Mapping and Characterization of the Functional Domains Responsible for the Differential Activity of the A and B Isoforms of the Human Progesterone Receptor* , 1997, The Journal of Biological Chemistry.
[256] D. Latchman,et al. Nerve growth factor up-regulates the transcriptional activity of CBP through activation of the p42/p44(MAPK) cascade. , 1998, The Journal of biological chemistry.
[257] M. Parker,et al. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. , 1993, Journal of cell science.
[258] T. Kitamoto,et al. p300 Mediates Functional Synergism between AF-1 and AF-2 of Estrogen Receptor α and β by Interacting Directly with the N-terminal A/B Domains* , 2000, The Journal of Biological Chemistry.
[259] S. Safe. Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. , 2001, Vitamins and hormones.
[260] Myles Brown,et al. Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription , 2000, Cell.
[261] J. Williamson,et al. THE INDUCTION OF OVULATION BY TAMOXIFEN , 1973, The Journal of obstetrics and gynaecology of the British Commonwealth.
[262] Sander Kersten,et al. Roles of PPARs in health and disease , 2000, Nature.
[263] M. Stallcup,et al. Synergistic Enhancement of Nuclear Receptor Function by p160 Coactivators and Two Coactivators with Protein Methyltransferase Activities* , 2001, The Journal of Biological Chemistry.
[264] Sandip K. Mishra,et al. Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor , 2000, Nature Cell Biology.
[265] B. O’Malley,et al. Acute Disruption of Select Steroid Receptor Coactivators Prevents Reproductive Behavior in Rats and Unmasks Genetic Adaptation in Knockout Mice EDE , 2002 .
[266] D. Forrest,et al. Requirement for thyroid hormone receptor beta in T3 regulation of cholesterol metabolism in mice. , 2002, Molecular endocrinology.
[267] D P McDonnell,et al. Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. , 1993, Molecular endocrinology.
[268] F. Melchior,et al. SUMO--nonclassical ubiquitin. , 2000, Annual review of cell and developmental biology.
[269] S. Yeh,et al. Suppression of Androgen Receptor Transactivation by Pyk2 via Interaction and Phosphorylation of the ARA55 Coregulator* , 2002, The Journal of Biological Chemistry.
[270] M Carlquist,et al. Structure of the ligand‐binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist , 1999, The EMBO journal.
[271] R. Evans,et al. Sharp, an inducible cofactor that integrates nuclear receptor repression and activation. , 2001, Genes & development.
[272] J. Yates,et al. A novel estrogen receptor α-associated protein, template-activating factor iβ, inhibits acetylation and transactivation , 2003 .
[273] Shih-Ming Huang,et al. Synergistic, p160 Coactivator-dependent Enhancement of Estrogen Receptor Function by CARM1 and p300* , 2000, The Journal of Biological Chemistry.
[274] J. Cidlowski,et al. Proteasome-mediated Glucocorticoid Receptor Degradation Restricts Transcriptional Signaling by Glucocorticoids* , 2001, The Journal of Biological Chemistry.
[275] K. Chwalisz,et al. Selective progesterone receptor modulators (SPRMs): a novel therapeutic concept in endometriosis. , 2002, Annals of the New York Academy of Sciences.
[276] H. Pols,et al. Distinct effects on the conformation of estrogen receptor alpha and beta by both the antiestrogens ICI 164,384 and ICI 182,780 leading to opposite effects on receptor stability. , 1999, Biochemical and biophysical research communications.
[277] T. Shiozawa,et al. Cyclic changes in the expression of steroid receptor coactivators and corepressors in the normal human endometrium. , 2003, The Journal of clinical endocrinology and metabolism.
[278] B. O’Malley,et al. The A and B forms of the chicken progesterone receptor arise by alternate initiation of translation of a unique mRNA. , 1987, Biochemical and biophysical research communications.
[279] Z. Nawaz,et al. Specific ubiquitin-conjugating enzymes promote degradation of specific nuclear receptor coactivators. , 2003, Molecular endocrinology.
[280] D. McDonnell,et al. RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. , 1994, The Journal of biological chemistry.
[281] A. Kralli,et al. A Tissue-Specific Coactivator of Steroid Receptors, Identified in a Functional Genetic Screen , 2000, Molecular and Cellular Biology.
[282] N. Spinner,et al. Unique forms of human and mouse nuclear receptor corepressor SMRT. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[283] S. Windahl,et al. The nuclear-receptor interacting protein (RIP) 140 binds to the human glucocorticoid receptor and modulates hormone-dependent transactivation , 1999, The Journal of Steroid Biochemistry and Molecular Biology.
[284] M Carlquist,et al. Structural insights into the mode of action of a pure antiestrogen. , 2001, Structure.
[285] V. Jordan. Biochemical pharmacology of antiestrogen action. , 1984, Pharmacological reviews.
[286] J. McNally,et al. The glucocorticoid receptor: rapid exchange with regulatory sites in living cells. , 2000, Science.
[287] S. Fawell,et al. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[288] J. Gustafsson,et al. Transcriptional synergism on the pS2 gene promoter between a p160 coactivator and estrogen receptor-alpha depends on the coactivator subtype, the type of estrogen response element, and the promoter context. , 2002, Molecular endocrinology.
[289] G. Martin,et al. Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. , 1994, Science.
[290] W. Chin,et al. Identification and Characterization of RRM-containing Coactivator Activator (CoAA) as TRBP-interacting Protein, and Its Splice Variant as a Coactivator Modulator (CoAM)* , 2001, The Journal of Biological Chemistry.
[291] P. Yen,et al. Physiological and molecular basis of thyroid hormone action. , 2001, Physiological reviews.
[292] Paul,et al. Advances in Brief In Breast Cancer , Amplification of the Steroid Receptor Coactivator Gene AIB 1 Is Correlated with Estrogen and Progesterone Receptor Positivity ’ , 2005 .
[293] M. Erdos,et al. Role of direct interaction in BRCA1 inhibition of estrogen receptor activity , 2001, Oncogene.
[294] P. Meltzer,et al. A Nuclear Factor, ASC-2, as a Cancer-amplified Transcriptional Coactivator Essential for Ligand-dependent Transactivation by Nuclear Receptors in Vivo * , 1999, The Journal of Biological Chemistry.
[295] M. Tzukerman,et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. , 1994, Molecular endocrinology.
[296] P. Chambon,et al. Role of the two activating domains of the oestrogen receptor in the cell‐type and promoter‐context dependent agonistic activity of the anti‐oestrogen 4‐hydroxytamoxifen. , 1990, The EMBO journal.
[297] Helmut Dotzlaw,et al. Expression of the steroid receptor RNA activator in human breast tumors. , 1999, Cancer research.
[298] M. Parker,et al. Molecular Determinants of the Estrogen Receptor-Coactivator Interface , 1999, Molecular and Cellular Biology.
[299] Russell Hilf,et al. The Effects of Estrogen-Responsive Element- and Ligand-Induced Structural Changes on the Recruitment of Cofactors and Transcriptional Responses by ERα and ERβ , 2002 .
[300] D. Kressler,et al. Regulation of the transcriptional coactivator PGC-1 via MAPK-sensitive interaction with a repressor , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[301] B. Spiegelman,et al. Degradation of the Peroxisome Proliferator-activated Receptor γ Is Linked to Ligand-dependent Activation* , 2000, The Journal of Biological Chemistry.
[302] B. Katzenellenbogen,et al. Conformational Changes and Coactivator Recruitment by Novel Ligands for Estrogen Receptor-α and Estrogen Receptor-β: Correlations with Biological Character and Distinct Differences among SRC Coactivator Family Members. , 2000, Endocrinology.
[303] P. Meltzer,et al. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[304] S. Robinson,et al. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. , 1988, Cancer research.
[305] A. Kornblihtt,et al. Antagonistic effects of T‐Ag and VP16 reveal a role for RNA pol II elongation on alternative splicing , 2001, The EMBO journal.
[306] R. Schüle,et al. FHL2, a novel tissue‐specific coactivator of the androgen receptor , 2000, The EMBO journal.
[307] P. Driggers,et al. Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling , 2002, Trends in Endocrinology & Metabolism.
[308] V. Ogryzko,et al. p300 and p300/cAMP-response Element-binding Protein-associated Factor Acetylate the Androgen Receptor at Sites Governing Hormone-dependent Transactivation* , 2000, The Journal of Biological Chemistry.
[309] K. Bramlett,et al. Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes. , 2001, Molecular endocrinology.
[310] E. Baracat,et al. Estrogen activity and novel tissue selectivity of delta8,9-dehydroestrone sulfate in postmenopausal women. , 1999, The Journal of clinical endocrinology and metabolism.
[311] Charles Kooperberg,et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.
[312] D. McDonnell,et al. Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists. , 2002, Molecular endocrinology.
[313] D. Fowlkes,et al. Peptide antagonists of the human estrogen receptor. , 1999, Science.
[314] S. Hilsenbeck,et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.
[315] E. Milgrom,et al. Sumoylation of the Progesterone Receptor and of the Steroid Receptor Coactivator SRC-1* , 2003, The Journal of Biological Chemistry.
[316] K.,et al. A new derivative of triphenylethylene: effect on implantation and mode of action in rats. , 1967, Journal of reproduction and fertility.
[317] D. Livingston,et al. Polyubiquitination of p53 by a Ubiquitin Ligase Activity of p300 , 2003, Science.
[318] J. Gustafsson,et al. Differential Response of Estrogen Receptor a and Estrogen Receptor b to Partial Estrogen Agonists/Antagonists , 1998 .
[319] V. Jordan. The strategic use of antiestrogens to control the development and growth of breast cancer. , 1992, Cancer.
[320] C. Turck,et al. Growth Factors Signal to Steroid Receptors through Mitogen-activated Protein Kinase Regulation of p160 Coactivator Activity* , 2001, The Journal of Biological Chemistry.
[321] B. O’Malley,et al. Regulation of Alternative Splicing by the ATP-Dependent DEAD-Box RNA Helicase p72 , 2002, Molecular and Cellular Biology.
[322] O. Jänne,et al. Involvement of Proteasome in the Dynamic Assembly of the Androgen Receptor Transcription Complex* , 2002, The Journal of Biological Chemistry.
[323] H. Kloosterboer. Tibolone: a steroid with a tissue-specific mode of action , 2001, The Journal of Steroid Biochemistry and Molecular Biology.
[324] H. Kloosterboer,et al. Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (±progestogen) treatments , 2002, The Journal of Steroid Biochemistry and Molecular Biology.
[325] Gregor Eichele,et al. Mutation of the Angelman Ubiquitin Ligase in Mice Causes Increased Cytoplasmic p53 and Deficits of Contextual Learning and Long-Term Potentiation , 1998, Neuron.
[326] Werner Rath,et al. Progestins, progesterone receptor modulators, and progesterone antagonists change VEGF release of endometrial cells in culture , 2000, Steroids.
[327] C C Glüer,et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.
[328] Y. Kong,et al. Dynamic inhibition of nuclear receptor activation by corepressor binding. , 2003, Molecular endocrinology.
[329] D. Bowtell,et al. Isolation and characterisation of murine homologues of the Drosophila seven in absentia gene (sina). , 1993, Development.
[330] K. Horwitz,et al. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. , 1997, Molecular endocrinology.
[331] H L Pearce,et al. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. , 2001, Cancer research.
[332] K.,et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[333] W. Chin,et al. Different DNA Elements Can Modulate the Conformation of Thyroid Hormone Receptor Heterodimer and Its Transcriptional Activity* , 1996, The Journal of Biological Chemistry.
[335] D. Kressler,et al. The PGC-1-related Protein PERC Is a Selective Coactivator of Estrogen Receptor α* , 2002, The Journal of Biological Chemistry.
[336] I. Rosewell,et al. The nuclear receptor co-repressor Nrip1 (RIP140) is essential for female fertility , 2000, Nature Medicine.